Knock-out mouse for Canavan disease: A model for gene transfer to the central nervous system

Journal of Gene Medicine

Volumn 2, Issue 3, 2000, Pages 165-175

  Matalon, Reuben ^a   Rady, Peter L ^a   Platt, Kenneth A ^b   Skinner, Henry B ^b   Quast, Michael J ^c   Campbell, Gerald A ^d   Matalon, Kimberlee ^a,e   Ceci, Jeffrey D ^a   Tyring, Stephen K ^a   Nehls, Michael ^b   Surendran, Sankar ^a   Wei, Jingna ^c   Ezell, Ed L ^c   Szucs, Sylvia ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b LEXICON PHARMACEUTICALS INC   (United States)

^c Anatomy and Neurosciences and Biomedical Engineering   (United States)

^d Department of Pathology ^*  (United States)

^e UNIVERSITY OF HOUSTON   (United States)

Author keywords

Aspartoacylase deficiency; Canavan disease; Central nervous system model; Knock out mouse; N acetylaspartic acid (NAA); Spongy degeneration of the brain

Indexed keywords

ANIMALIA; MURINAE;

AMIDASE; ASPARTOACYLASE;

ANIMAL; ARTICLE; BRAIN; CANAVAN DISEASE; CENTRAL NERVOUS SYSTEM; CONGENITAL MALFORMATION; DISEASE MODEL; GENE THERAPY; GENE TRANSFER; GENETICS; METABOLISM; MOLECULAR CLONING; MOUSE; MOUSE MUTANT; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PHENOTYPE;

AMIDOHYDROLASES; ANIMALS; BRAIN; CANAVAN DISEASE; CENTRAL NERVOUS SYSTEM; CLONING, MOLECULAR; DISEASE MODELS, ANIMAL; GENE THERAPY; GENE TRANSFER TECHNIQUES; MAGNETIC RESONANCE IMAGING; MICE; MICE, KNOCKOUT; PHENOTYPE;

EID: 0034182887     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1521-2254(200005/06)2:3<165::aid-jgm107>3.0.co;2-r     Document Type: Article

References (57)

1. Matalon R, Michals-Matalon K. Molecular basis of Canavan Disease. Eur J Pediatr Neurol 1998; 2: 69-76.
2. Globus JH, Strauss I. Progressive degenerative subcortical encephalopathy (Schilder's disease). Arch Neurol Psychiatr 1928; 28: 1190-1228.
3. Canavan MM. Schilder's Encephalitis Periaxialis Diffusa. Arch Neurol Psychiatr 1931; 25: 299-308.
4. Van Bogaert L, Bertrand I. Sur une idiotie familiale avec degerescense sponglieuse de neuraxe (note preliminaire). Acta Neurol Belg 1949; 49: 572-587.
5. Matalon R, Michals K, Sebasta D, Deanching M, Gashkoff P, Casanova J. Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan Disease. Am J Med Genet 1988; 29: 463-471.
6. Birnbaum SM, Levintow L, Kingsley RB, Greenstein JP. Specificity of amino acid acylases. J Biol Chem 1952; 194: 455-462.
7. Tallan HH, Moore S, Stein WH. N-Acetyl-L-aspartic acid in brain. J Biol Chem 1956; 219: 257-264.
8. Goldstein FB. Biosynthesis of N-acetyl-L-aspartic acid. J Biol Chem 1959; 234: 2702-2706.
9. Goldstein FB. The enzymatic synthesis of N-acetyl-L-aspartic acid by subcellular preparations of rat brain. J Biol Chem 1969; 244: 4257-4260.
10. Miyake M, Kakimoto Y, Sorimachi M. A gas Chromatographic method for the determination of N-acetyl-L-aspartic acid, N-acetyl-aspartylglutamic acid and beta-citryl-L-glutamic acid and their distributions in the brain and other organs of various species of animals. J Neurochem 1980; 36: 804-810.
11. Jacobson KB. Studies on the role of N-acetylaspartic acid in mammalian brain. J Gen Physiol 1957; 43: 323-333.
12. McIntosh JM, Cooper JR. Studies on the function of N-acetylaspartic acid in the brain. J Neurochem 1965; 12: 825-835.
13. Kaul RK, Casanova J, Johnson A, Tang P, Matalon R. Purification, characterization and localization of aspartoacylase from bovine brain. J Neurochem 1991; 56: 129-135.
14. Johnson A, Kaul R, Casanova J, Matalon R. Aspartoacylase, the deficient enzyme in spongy degeneration (Canavan disease) is a myelin-associated enzyme. J Neuropathol Exp Neurol 1989; 48: 348
15. Kaul R, Gao GP, Balamurugan K, Matalon R. Human asparto-acylase cDNA and mis-sense mutation in Canavan disease. Nat Genet 1993; 5: 118-123.
16. Kaul R, Balamurugan K, Gao GP, Matalon R. Canavan disease: Genomic organization and localization of Human ASPA to 17p13-ter and conservation of the ASPA gene during evolution. Genomics 1994; 21: 364-370.
17. Kaul R, Gao GP, Aloya M, Balamurugan K, Petrosky A, Michals K, Matalon R. Canavan disease: mutations among Jewish and non-Jewish patients. Am J Hum Genet 1994; 55: 34-41.
18. Kaul R, Gao GP, Michals K, Whelan DT, Levin S, Matalon R. A novel (cys 152>arg) missense mutation in Arab patient with Canavan disease. Hum Mutat 1995; 5: 269-271.
19. Kaul R, Gao GP, Matalon R, Aloya M, Su Q, Jin M, Johnson AB, Schutgens RB, Clarke JT. Identification and expression of eight novel mutations among non-Jewish patients with Canavan disease. Am J Hum Genet 1996; 59: 95-102.
20. Shaag A, Anikster Y, Christensen E, et al. The molecular basis of Canavan (aspartoacylase deficiency) disease in European non-Jewish patients. Am J Hum Genet 1995; 57: 572-580.
21. Kobayashi K, Tsujino S, Ezoe T, Hamaguchi H, Nihei K, Sakuragawa N. A missense mutation (I143T) in a Japanese patient with Canavan disease. Hum Mutat 1998; 1: 308S-309S.
22. Rady PL, Vargas T, Tyring SK, Matalon RM, Langenbeck U. Novel missense mutation (Y231C) in a Turkish patient with Canavan disease. Am J Med Genet 1999; 87: 273-275.
23. Matalon R, Michals-Matalon K. Recent advances in Canavan disease. Adv Pediatr 1999; 46: 493-506.
24. Matalon R, Kaul R, Michals K. Carrier rate of Canavan disease among Ashkenazi Jewish individuals. Am J Hum Genet 1994; 55: 908A
25. Kronn D, Oddoux C, Phillips J, Ostrer H. Prevalence of Canavan disease heterozygotes in the New York metropolitan Ashkenazi Jewish population. Am J Hum Genet 1995; 57: 1250-1252.
26. ACOG Committee Opinion. Screening for Canavan Disease. Committee on Genetics, American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 1999; 65: 91-92.
27. During MJ. Gene trial in New Zealand. Lancet 1996; 348: 618
28. Wattler S, Kelly M, Nehls M. Construction of gene targeting vectors from λKOS genomic libraries. BioTechniques 1999; 26: 1150-1160.
29. Nehls M, Kyewski B, Messerle M, Waldschutz R, Schuddekopf K, Smith AJ, Boehm T. Two genetically separable steps in the differentiation of thymic epithelium. Science 1996; 272: 886-889.
30. Zheng B, Sage M, Cai WW, Thompson DM, Tavsanli BC, Cheah YC, Bradley A. Engineering a mouse balancer chromosome. Nat Genet 1999; 4: 375-378.
31. Goodman SI, Markey SP. Diagnosis of Organic Acidemias by Gas Chromatography-Mass Spectrometry. Alan R. Liss, Inc.: New York, 1981; 1-43.
32. Bottomley PA. Spatial localization in NMR spectroscopy in vivo. Ann N Y Acad Sci 1987; 508: 333-348.
33. Pioro EP, Wang Y, Moore JK, Ng TC, Trapp BD, Klinkosz B, Mitsumoto H. Neuronal pathology in the wobbler mouse brain revealed by in vivo proton magnetic resonance spectroscopy and immunocytochemistry. Neuroreport 1998; 14: 3041-3046.
34. Ingram DK. Toward the behavioral assessment of biological aging in the laboratory mouse: Concepts, terminology, and objectives. Exp Aging Res 1983; 9: 225-238.
35. Matalon R, Kaul R, Michals K. Canavan Disease. In The Molecular and Genetic Basis of Neurological Disease. Rosenberg RN, Prusiner SB, Di Mauro S, Barchi RL (eds). Butterworth-Heinemann: Boston, MA, 1997; 493-502.
36. Smithies O. Animal models of human genetic diseases. Trends Genet 1993; 9: 112-116.
37. Hagan G, Bjerkas I. Spongy degeneration of white matter in the central nervous system of silver foxes (Vulpes vulpes). Vet Pathol 1990; 27: 187-193.
38. Zachary JF, O'Brien CP. Spongy degeneration of the central nervous system in two canine litter mates. Vet Pathol 1985; 22: 561-567.
39. Mason RW, Hartley WJ, Randall M. Spongiform generation of the white matter in a Saymoyed pup. Aust Vet Pract 1979; 9: 11-13.
40. Azzam NA, Bready JV, Vinters HV, Camcilla PA. Spontaneous spongy degeneration of the mouse brain. J Neuropathol Exp Neurol 1984; 43: 118-130.
41. Sager TN, Thomsen C, Laursen JS, Hansen AJ. Astroglia contain a specific transport mechanism for N-acetyl-L-aspartate. J Neurochem 1999; 2: 807-811.
42. Dunlop DS, McHale DM, Lajtha A. Decreased brain N-acetyl-aspartate in Huntington's disease. Brain Res 1992; 580: 44
43. 1H magnetic resonance spectroscopic imaging. Neurology 1993; 43: 509-515.
44. Meyerhoff DJ, Bloomer C, Cardenas V, Norman D, Weiner MW, Fein G. Elevated subcortical choline metabolites in cognitively and clinically asymptomatic HIV+ patients. Neurology 1999; 5: 995-1003.
45. Gideon P, Henrikson O, Sperling B, Christiansen P, Olsen TS, Jorgense HS, Arlien-Soborg P. Early time course of N-acetylaspartate, creatine and phosphocreatine, and compounds containing choline in the brain after acute stroke: a proton magnetic resonance spectroscopy study. Stroke 1992; 23: 1566-1572.
46. Pereira AC, Saunders DE, Doyle VL, Bland JM, Howe FA, Griffiths JR, Brown MM. Measurement of initial N-acetyl aspartate concentration by magnetic resonance spectroscopy and initial infarct volume by MRI predicts outcome in patients with middle cerebral artery territory infarction. Stroke 1999; 8: 1577-1582.
47. Stevens H, Jakobs C, de Jager AE, Cunningham RT, Korf J. Neuron-specific enolase and N-acetyl-aspartate as potential peripheral markers of ischaemic stroke. Eur J Clin Invest 1999; 1: 6-11.
48. Marcucci F, Colombo L, De Ponte G, Mussimi E. Decrease in N-acetylaspartic acid in brain of myodystrophic mice. J Neurochem 1984; 43: 1484-1486.
49. Akiguchi I, Nakano S, Shiino A, Kimura R, Inubushi T, Handa J, Nakamura M, Tanaka M, Oka N, Kimura J. Brain proton magnetic resonance spectroscopy and brain atrophy in myotonic dystrophy. Arch Neurol 1999; 3: 325-330.
50. Bell JD, Cox IJ, Williams SC, Belton PS, McConnell I, Hope J. In vivo detection of metabolic changes in a mouse model of scrapie using nuclear magnetic resonance spectroscopy. J Gen Virol 1991; 72: 2419-2423.
51. Jaarsma D, Veenma-van der Duin L, Korf J. N-Acetylaspartate and N-acetyl aspartyl-glutamate levels in Alzheimer's disease post-mortem brain tissue. J Neurol Sci 1994; 127: 230
52. Taylor-Robinson SD, Turjanski N, Bhattacharya S, Seery JP, Sargentoni J, Brooks DJ, Bryant DJ, Cox IJ. A proton magnetic resonance spectroscopy study of the striatum and cerebral cortex in Parkinson's disease. Metab Brain Dis 1999; 14: 45-55.
53. Li SJ, Wang Y, Pankiewicz J, Stein EA. Neurochemical adaptation to cocaine abuse: reduction of N-acetyl aspartate in thalamus of human cocaine abusers. Biol Psychiatry 1999; 11: 1481-1487.
54. McConnell JR. Reduced levels of N-acetylaspartate in malignant brain tumors. CA Cancer J Clin 1999; 3: 192
55. Baslow MH. Molecular water pumps and the aetiology of Canavan disease: a case of the sorcerer's apprentice. J Inherit Metab Dis 1999; 2: 99-101.
56. McIntosh JM, Cooper JR. Studies on the function of N-acetylaspartic acid in the brain. J Neurochem 1965; 12: 825-835.
57. Shigematsu H, Okamura N, Shimeno H, Kishimoto Y, Kan L, Feuselean C. Purification and characterization of the heat stable factors essential for conversion of lignoceric acid to cerebronic acid and glutamic acid: identification of N-acetyl-L-aspartic acid. J Neurochem 1983; 40: 814-820.